Oppenheimer Asset Management Inc. Acquires 1,035 Shares of Alexion Pharmaceuticals (ALXN)

Oppenheimer Asset Management Inc. increased its holdings in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 4.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,235 shares of the biopharmaceutical company’s stock after acquiring an additional 1,035 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $2,590,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ALXN. Schwab Charles Investment Management Inc. boosted its position in Alexion Pharmaceuticals by 6.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 906,805 shares of the biopharmaceutical company’s stock worth $108,445,000 after acquiring an additional 56,472 shares during the last quarter. Lourd Capital LLC acquired a new position in Alexion Pharmaceuticals during the fourth quarter worth about $221,000. Robeco Institutional Asset Management B.V. boosted its position in Alexion Pharmaceuticals by 50.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 15,980 shares of the biopharmaceutical company’s stock worth $1,908,000 after acquiring an additional 5,375 shares during the last quarter. Twin Capital Management Inc. boosted its position in Alexion Pharmaceuticals by 26.5% during the fourth quarter. Twin Capital Management Inc. now owns 38,786 shares of the biopharmaceutical company’s stock worth $4,638,000 after acquiring an additional 8,136 shares during the last quarter. Finally, Northern Capital Management LLC acquired a new position in Alexion Pharmaceuticals during the fourth quarter worth about $570,000. Hedge funds and other institutional investors own 92.40% of the company’s stock.

A number of research firms recently weighed in on ALXN. Stifel Nicolaus boosted their price target on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the stock a “buy” rating in a research report on Friday, April 27th. Evercore ISI upgraded shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 10th. Nomura lifted their target price on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a research note on Thursday, March 15th. Finally, Robert W. Baird set a $160.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $155.52.

In other news, EVP Julie O’neill sold 1,625 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $119.83, for a total value of $194,723.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Heidi L. Wagner sold 698 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total transaction of $83,306.30. The disclosure for this sale can be found here. 4.35% of the stock is currently owned by insiders.

Shares of Alexion Pharmaceuticals opened at $117.74 on Friday, Marketbeat.com reports. The stock has a market cap of $26.20 billion, a price-to-earnings ratio of 22.82, a PEG ratio of 1.06 and a beta of 1.11. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a current ratio of 3.35, a quick ratio of 2.86 and a debt-to-equity ratio of 0.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.18. The business had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.38 EPS. research analysts anticipate that Alexion Pharmaceuticals will post 6.28 EPS for the current fiscal year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply